[March 29, 2018] |
|
Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD) Report 2018 - ResearchAndMarkets.com
The "Market
Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)?"
report has been added to ResearchAndMarkets.com's
offering.
This Market Spotlight report covers the Attention Deficit Hyperactivity
Disorder (ADHD) market, comprising key pipeline and marketed drugs,
clinical trials, upcoming and regulatory events, patent information, a
10-year disease prevalence forecast, and licensing and acquisition
deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
-
The author estimates that in 2016, there were 175.1 million prevalent
cases of attention deficit hyperactivity disorder (ADHD) in people
aged 5-44 years worldwide, and forecasts that number to increase to
185.5 million prevalent cases by 2025.
-
The worldwide prevalence of ADHD among children aged 5-19 years is
estimated to be 5.29%, while the prevalence among adults aged 20-44
years is estimated to be 2.80%.
-
The majority of approved drugs in the ADHD space target dopamine,
dopamine reuptake, norepinephrine (noradrenaline), norepinephrine
(noradrenaline) reuptake/transporter, and alpha 2 adrenergic
receptors. Most of the drugs are commonly administered via the oral
route, however, a few products are available in topica and intranasal
formulations.
-
The majority of industry-sponsored drugs in active clinical
development for ADHD are in Phase II. Therapies in mid-to-late stage
development for ADHD focus on a wide variety of targets. Among these
therapies, Benjorna (methylphenidate) is closest to market. The
majority of the pipeline drugs in mid-to-late-stage development for
ADHD are administered via the oral route.
-
High-impact upcoming events for drugs in the ADHD space include the US
Food and Drug Administration's decision on NDAs for Benjorna and
dasotraline, and topline Phase II results for AEVI-001.
-
There were 14 licensing and asset acquisition deal agreements during
2013-17. Impax Laboratories' acquisition of certain assets related to
generic products from Teva and Allergan, for $586m, was the largest
deal during the period.
-
Vyvanse's (lisdexamfetamine dimesylate) sales have ranked highest in
the ADHD space during 2012-16 and are forecast to remain the highest
during the forecast period (2017-22).
-
The clinical trials distribution across Phase I-IV indicates that
there is an even distribution of trials for ADHD, with 45.5% of trials
in Phase I-II, and 54.5% in Phase III-IV.
-
The US has a substantial lead in the number of ADHD clinical trials
globally. Germany leads the major EU markets, while Japan has the top
spot in Asia.
-
Clinical trial activity in the ADHD space is dominated by completed
trials. Shire has the highest number of completed clinical trials for
ADHD, with 144 completed trials.
-
Shire has carried out the most Phase III trials in ADHD, followed by
Eli Lilly, which has sponsored 50 Phase III trials.
Key Topics Covered:
1 Key Takeaways
2 Disease Background
3 Treatment
4 Epidemiology
5 Marketed Drugs
6 Pipeline Drugs
7 Key Upcoming Events
8 Licensing And Asset Acquisition Deals
9 Parent Patents
10 Revenue Opportunity
11 Clinical Trial Landscape
12 Bibliography
For more information about this report visit https://www.researchandmarkets.com/research/st9zxt/market_spotlight?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180329005493/en/
[ Back To TMCnet.com's Homepage ]
|